Dr. Ramasamy discusses myths about testosterone therapy

Researchers still urge caution when considering testosterone therapy.

Hamilton discusses findings from a recent study published in European Urology.

Kyzatrex is an oral testosterone replacement therapy for the treatment of adult males with conditions associated with hypogonadism.

Testosterone undecanoate (Tlando), an oral testosterone replacement therapy, was approved in March 2022 for the treatment of men with hypogonadism.

The pivotal trial supporting approval of the oral testosterone undecanoate was Study 16-002, which included 95 hypogonadal males.

"We didn't see any clinically significant changes on the prostate gland, which is very important for the urologists who see people who have prostate cancer or prostate enlargement," says Ronald Swerdloff, MD.